HC Wainwright started coverage on shares of Replimune Group (NASDAQ:REPL) in a research note released on Monday, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $26.00 price target on the stock.
REPL has been the topic of a number of other reports. Zacks Investment Research raised shares of HB Fuller from a sell rating to a hold rating in a report on Wednesday, July 3rd. Wedbush cut their price target on shares of Eiger Biopharmaceuticals from $43.00 to $35.00 and set an outperform rating on the stock in a report on Wednesday, April 24th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $24.67.
Shares of NASDAQ:REPL traded down $0.80 during midday trading on Monday, reaching $13.13. The company had a trading volume of 29,148 shares, compared to its average volume of 63,930. The stock has a 50 day simple moving average of $13.60. The company has a debt-to-equity ratio of 0.05, a quick ratio of 14.26 and a current ratio of 14.26. The stock has a market capitalization of $443.61 million and a PE ratio of -9.87. Replimune Group has a 52-week low of $8.88 and a 52-week high of $23.55.
About Replimune Group
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.